Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 8
2005 2
2006 4
2007 3
2008 6
2009 2
2010 2
2011 3
2013 1
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Danger ahead: COVID-19 infections after vaccination.
Greenberger LM, Nichols GL. Greenberger LM, et al. Blood. 2022 Mar 10;139(10):1429-1430. doi: 10.1182/blood.2021014505. Blood. 2022. PMID: 35267005 Free PMC article. No abstract available.
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: greenberger lm. EClinicalMedicine. 2023 May;59:101983. doi: 10.1016/j.eclinm.2023.101983. Epub 2023 Apr 27. EClinicalMedicine. 2023. PMID: 37128256 Free PMC article.
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: greenberger lm. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. PMID: 38343800 Free PMC article. Preprint.
The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.
Luttwak E, Noy A, Seshan V, Saltzman LA, Greenberger LM. Luttwak E, et al. Among authors: greenberger lm. Leuk Lymphoma. 2023 Oct;64(10):1727-1729. doi: 10.1080/10428194.2023.2227749. Epub 2023 Jun 29. Leuk Lymphoma. 2023. PMID: 37384591 Free PMC article. No abstract available.
43 results